Beam Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
BEAM$27.02+2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $230,203 | $435,895 |
| Marketable securities | 695,554 | 753,981 |
| Prepaid expenses and other current assets | 19,777 | 21,167 |
| Total current assets | 945,534 | 1,211,043 |
| Property and equipment, net | 113,502 | 124,960 |
| Restricted cash | 6,549 | 8,719 |
| Operating lease right-of-use assets | 104,704 | 112,846 |
| Other assets | 1,078 | 2,146 |
| Total assets | $1,171,367 | $1,459,714 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,812 | $1,617 |
| Accrued expenses and other current liabilities | 51,769 | 111,664 |
| Current portion of derivative liabilities | 8,400 | 10,800 |
| Current portion of deferred revenue | 89,327 | 68,706 |
| Current portion of lease liability | 12,936 | 12,778 |
| Total current liabilities | 166,244 | 205,565 |
| Long-term lease liability | 149,129 | 159,911 |
| Contingent consideration liabilities | 1,104 | 2,723 |
| Long-term portion of deferred revenue | 57,816 | 109,888 |
| Long-term portion of derivative liabilities | 5,276 | — |
| Other liabilities | 481 | 298 |
| Total liabilities | 380,050 | 478,385 |
| Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.01 par value; 250,000,000 shares authorized, 82,558,883 and 81,632,496 issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 826 | 816 |
| Additional paid-in capital | 2,265,009 | 2,169,798 |
| Accumulated other comprehensive (loss) income | 1,759 | 604 |
| Accumulated deficit | (1,476,277) | (1,189,889) |
| Total stockholders’ equity | 791,317 | 981,329 |
| Total liabilities and stockholders’ equity | $1,171,367 | $1,459,714 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.